Bevacizumab Use in End-Stage Renal Disease: Key Considerations

Introduction to Bevacizumab Therapy

• The National Comprehensive Cancer Network recommends bevacizumab for metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and cervical cancer, with established efficacy for these indications 1, 2, 3

Clinical Decision Making

• For hemodialysis patients, bevacizumab can be administered, but timing relative to dialysis sessions should follow standard ESRD medication principles—give after dialysis to prevent premature drug removal 4
• Avoid bevacizumab in patients with recent hemoptysis, particularly relevant for lung cancer patients, due to increased risk of bleeding 2

Dosing and Monitoring

• Standard bevacizumab dosing does not require adjustment for renal impairment, but the drug's nephrotoxic effects must be considered 3
• The recommended dosing for metastatic colorectal cancer is 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks 1
• For non-squamous NSCLC, the recommended dosing is 15 mg/kg every 3 weeks 2
• For metastatic renal cell carcinoma, the recommended dosing is 10 mg/kg every 2 weeks 3

Critical Pitfalls to Avoid

• Do not combine bevacizumab with antiplatelet therapy (including low-dose aspirin) in ESRD patients without compelling indication, as this substantially elevates bleeding risk 5
• Permanently discontinue bevacizumab for Grade 4 hemorrhage 2